Bionano Genomics and Greenwood Genetic Center have announced a study published in Genome Research, marking the first use of optical genome mapping (OGM) to explore the genetic factors behind neural ...
SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025.
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and ...
The optical genome mapping market is poised for substantial growth, expanding from $0.23 billion in 2025 to $0.29 bi ...
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) ...
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key ...
Detailed price information for Bionano Genomics Inc (BNGO-Q) from The Globe and Mail including charting and trades.
After market closed today, Bionano issued a press release announcing its financial results for the fourth quarter of 2024. A copy of the release can be found on the investor relations page of the ...
Bionano Genomics, Inc. beats earnings expectations. Reported EPS is $-1.59292, expectations were $-1.81. Operator: Good day, and welcome to the Bionano Third Quarter 2025 Earnings Conference Call.
Image source: The Motley Fool. Management attributed revenue softness to supply constraints in consumables, not demand weakness, and indicated expected recovery as manufacturing delays are resolved.